Technology
Health
Biotechnology
Vital Therapies
$0.2189876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$0.218
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.0098 (4.66%) Today
-$0.0019 (-0.86%) After Hours
Why Robinhood?
You can buy or sell VTL and other stocks, options, ETFs, and crypto commission-free!
About
Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. Read More The company was founded in May 2003 and is headquartered in San Diego, CA.
Employees
10
Headquarters
San Diego, California
Founded
2003
Market Cap
8.90M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
2.15M
High Today
$0.2293
Low Today
$0.214
Open Price
$0.2293
Volume
457.44K
52 Week High
$9.75
52 Week Low
$0.151
Collections
Technology
Health
Biotechnology
Therapy
2014 IPO
US
North America
News
MarketBeatFeb 27
Stock Price, News, & Analysis for Vital Therapies
Vital Therapies, Inc., a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, In...
Price Paid on Robinhood
27% Lower
Right Now
52 Week Low
$0.151
Average Price Paid
$0.2985
52 Week High
$9.75
Earnings
-$0.35
-$0.25
-$0.16
-$0.06
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 7, After Hours